Q-omics provides the consensus-scored ADPGK profile across patient tissues and cancer cell-line models. ADPGK expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADPGK is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ADPGK protein abundance shows 20,469 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where ADPGK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADPGK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADPGK survival associations across molecular data types. ADPGK RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADPGK RNA expression–survival associations across cancer types. High ADPGK expression shows unfavorable associations in UVM, ACC, LGG, KIRC, MESO and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ADPGK RNA expression.
This table summarizes ADPGK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADPGK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADPGK shows higher tumor expression in HNSC, KIRC, BLCA, STAD, LIHC and COAD. The HNSC box plot shows higher ADPGK RNA expression in tumor versus normal tissue (log2 FC = +1.234, t-test p < 0.001).
This table shows molecular features associated with ADPGK in patient tissues and cancer cell lines. In patient samples, ADPGK shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADPGK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
